Cargando…
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643639/ https://www.ncbi.nlm.nih.gov/pubmed/32960498 http://dx.doi.org/10.1002/cam4.3454 |
_version_ | 1783606316724387840 |
---|---|
author | Zheng, Guoqiao Sundquist, Kristina Sundquist, Jan Försti, Asta Hemminki, Akseli Hemminki, Kari |
author_facet | Zheng, Guoqiao Sundquist, Kristina Sundquist, Jan Försti, Asta Hemminki, Akseli Hemminki, Kari |
author_sort | Zheng, Guoqiao |
collection | PubMed |
description | BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. RESULTS: Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. CONCLUSIONS: Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification. |
format | Online Article Text |
id | pubmed-7643639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76436392020-11-13 Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor Zheng, Guoqiao Sundquist, Kristina Sundquist, Jan Försti, Asta Hemminki, Akseli Hemminki, Kari Cancer Med Cancer Prevention BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. RESULTS: Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. CONCLUSIONS: Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification. John Wiley and Sons Inc. 2020-09-22 /pmc/articles/PMC7643639/ /pubmed/32960498 http://dx.doi.org/10.1002/cam4.3454 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Zheng, Guoqiao Sundquist, Kristina Sundquist, Jan Försti, Asta Hemminki, Akseli Hemminki, Kari Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title | Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_full | Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_fullStr | Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_full_unstemmed | Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_short | Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_sort | rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643639/ https://www.ncbi.nlm.nih.gov/pubmed/32960498 http://dx.doi.org/10.1002/cam4.3454 |
work_keys_str_mv | AT zhengguoqiao ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT sundquistkristina ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT sundquistjan ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT forstiasta ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT hemminkiakseli ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT hemminkikari ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor |